Related references
Note: Only part of the references are listed.Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research
Denis Fourches et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
An Analysis of the Binding Efficiencies of Drugs and Their Leads in Successful Drug Discovery Programs
Emanuele Perola
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Assessment of the blood-brain barrier in CNS drug discovery
Phil Jeffrey et al.
NEUROBIOLOGY OF DISEASE (2010)
Reaching Out to Collaborators: Crowdsourcing for Pharmaceutical Research
Sean Ekins et al.
PHARMACEUTICAL RESEARCH (2010)
Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds
Christian Tyrchan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Using the Golden Triangle to optimize clearance and oral absorption
Ted W. Johnson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability
Michael J. Waring
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds
Jens-Uwe Peters et al.
CHEMMEDCHEM (2009)
Receptor Occupancy and Brain Free Fraction
Jeanette Watson et al.
DRUG METABOLISM AND DISPOSITION (2009)
Structure and organization of drug-target networks: insights from genomic approaches for drug discovery
Sarath Chandra Janga et al.
MOLECULAR BIOSYSTEMS (2009)
The influence of lead discovery strategies on the properties of drug candidates
Gyoergy M. Keserue et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Generation of a set of simple, interpretable ADMET rules of thumb
M. Paul Gleeson
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Network pharmacology: the next paradigm in drug discovery
Andrew L. Hopkins
NATURE CHEMICAL BIOLOGY (2008)
Are the Chemical Structures in Your QSAR Correct?
Douglas Young et al.
QSAR & COMBINATORIAL SCIENCE (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Drug-target network
Muhammed A. Yildirim et al.
NATURE BIOTECHNOLOGY (2007)
The human disease network
Kwang-Il Goh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Fragments, network biology and designing multiple ligands
Richard Morphy et al.
DRUG DISCOVERY TODAY (2007)
Lead-like, drug-like or pub-like: how different are they?
Tudor I. Oprea et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development
Richard W. Peck
DRUG DISCOVERY TODAY (2007)
Opinion - How many drug targets are there?
John P. Overington et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Fragment-based drug design: How big is too big?
Philip J. Hajduk
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Dependence of molecular properties on proteomic family for marketed oral drugs
Michal Vieth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds
Richard Morphy
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Biological assay challenges from compound solubility: strategies for bioassay optimization
L Di et al.
DRUG DISCOVERY TODAY (2006)
Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain
SG Summerfield et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
T Wunberg et al.
DRUG DISCOVERY TODAY (2006)
Can we rationally design promiscuous drugs?
AL Hopkins et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2006)
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor
Karen E. Lackey
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Avoiding physicochemical artefacts in early ADME-Tox experiments
Robert S. DeWitte
DRUG DISCOVERY TODAY (2006)
Predicting protein druggability
PJ Hajduk et al.
DRUG DISCOVERY TODAY (2005)
A comprehensive listing of bioactivation pathways of organic functional groups
AS Kalgutkar et al.
CURRENT DRUG METABOLISM (2005)
The evolution of synthetic oral drug properties
JR Proudfoot
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Components of successful lead generation
AM Davis et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Time-related differences in the physical property profiles of oral drugs
PD Leeson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Pursuing the leadlikeness concept in pharmaceutical research
MM Hann et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2004)
The discovery of tadalafil:: A novel and highly selective PDE5 inhibitor.: 1:: 5,6,11,11a-tetrahydro-1H-imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues
A Daugan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
A comparison of physiochemical property profiles of development and marketed oral drugs
MC Wenlock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Is there a difference between leads and drugs? A historical perspective
TI Oprea et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2001)
Molecular complexity and its impact on the probability of finding leads for drug discovery
MM Hann et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2001)
Share Paper
